MRSA: Methicillin-resistant Staphylococcus aureus; MSSA:
Methicillin-sensitive Staphylococcus aureus
PHARMACOKINETICSÂ
Orally administered faropenem medoxomil is readily absorbed. The
addition of the medoxomil ester to the faropenem moiety improves
bioavailability. The bioavailability of faropenem medoxomil is proposed
to be 70–80%, which is approximately four times that of faropenem
sodium.11https://m.chemicalbook.com/Article/Pharmacokinetics-of-Faropenem.htm
[accessed May 18 2023] The half-life of faropenem medoxomil is
estimated to be 0.9 hours. Administration of faropenem medoxomil under
fasting and postprandial conditions resulted in no significant
difference in Cmax and AUC.
Clinical Evidence for
Faropenem